181 related articles for article (PubMed ID: 38057321)
1. The PENGUIN approach to reconstruct protein interactions at enhancer-promoter regions and its application to prostate cancer.
Armaos A; Serra F; Núñez-Carpintero I; Seo JH; Baca SC; Gustincich S; Valencia A; Freedman ML; Cirillo D; Giambartolomei C; Tartaglia GG
Nat Commun; 2023 Dec; 14(1):8084. PubMed ID: 38057321
[TBL] [Abstract][Full Text] [Related]
2. H3K27ac HiChIP in prostate cell lines identifies risk genes for prostate cancer susceptibility.
Giambartolomei C; Seo JH; Schwarz T; Freund MK; Johnson RD; Spisak S; Baca SC; Gusev A; Mancuso N; Pasaniuc B; Freedman ML
Am J Hum Genet; 2021 Dec; 108(12):2284-2300. PubMed ID: 34822763
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of prostate specific membrane antigen/folate hydrolase transcription by an enhancer.
Noss KR; Wolfe SA; Grimes SR
Gene; 2002 Feb; 285(1-2):247-56. PubMed ID: 12039052
[TBL] [Abstract][Full Text] [Related]
4. Three-dimensional genome architectural CCCTC-binding factor makes choice in duplicated enhancers at Pcdhα locus.
Wu Y; Jia Z; Ge X; Wu Q
Sci China Life Sci; 2020 Jun; 63(6):835-844. PubMed ID: 32249388
[TBL] [Abstract][Full Text] [Related]
5. Development of a new plasmid vector with PSA-promoter and enhancer expressing tissue-specificity in prostate carcinoma cell lines.
Lee SE; Jin RJ; Lee SG; Yoon SJ; Park MS; Heo DS; Choi H
Anticancer Res; 2000; 20(1A):417-22. PubMed ID: 10769689
[TBL] [Abstract][Full Text] [Related]
6. Tissue-selective RNA interference in prostate cancer cell using prostate specific membrane antigen promoter/enhancer.
Zhao W; Xu Y; Kong D; Liu R; Zhang Z; Jin C; Zhang Z; Xiu Y
Urol Oncol; 2009; 27(5):539-47. PubMed ID: 18639471
[TBL] [Abstract][Full Text] [Related]
7. CTCF mediates the TERT enhancer-promoter interactions in lung cancer cells: identification of a novel enhancer region involved in the regulation of TERT gene.
Eldholm V; Haugen A; Zienolddiny S
Int J Cancer; 2014 May; 134(10):2305-13. PubMed ID: 24174344
[TBL] [Abstract][Full Text] [Related]
8. Prostate targeting: PSP94 gene promoter/enhancer region directed prostate tissue-specific expression in a transgenic mouse prostate cancer model.
Gabril MY; Onita T; Ji PG; Sakai H; Chan FL; Koropatnick J; Chin JL; Moussa M; Xuan JW
Gene Ther; 2002 Dec; 9(23):1589-99. PubMed ID: 12424611
[TBL] [Abstract][Full Text] [Related]
9. CRISPR-mediated deletion of prostate cancer risk-associated CTCF loop anchors identifies repressive chromatin loops.
Guo Y; Perez AA; Hazelett DJ; Coetzee GA; Rhie SK; Farnham PJ
Genome Biol; 2018 Oct; 19(1):160. PubMed ID: 30296942
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector.
Latham JP; Searle PF; Mautner V; James ND
Cancer Res; 2000 Jan; 60(2):334-41. PubMed ID: 10667585
[TBL] [Abstract][Full Text] [Related]
11. [Constructing recombinant plasmid with prostate-specific membrane antigen promoter and reverse enhancer and comparing the transcription activity of enhancers in different directions].
Zeng H; Liao YC; Wang F; Wu Q; Yang YR
Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 Nov; 36(6):782-5. PubMed ID: 16334552
[TBL] [Abstract][Full Text] [Related]
12. Functional characterization of the GDEP promoter and three enhancer elements in retinoblastoma and prostate cell lines.
Cross DS; Burmester JK
Med Oncol; 2008; 25(1):40-9. PubMed ID: 18188713
[TBL] [Abstract][Full Text] [Related]
13. MYC reshapes CTCF-mediated chromatin architecture in prostate cancer.
Wei Z; Wang S; Xu Y; Wang W; Soares F; Ahmed M; Su P; Wang T; Orouji E; Xu X; Zeng Y; Chen S; Liu X; Jia T; Liu Z; Du L; Wang Y; Chen S; Wang C; He HH; Guo H
Nat Commun; 2023 Mar; 14(1):1787. PubMed ID: 36997534
[TBL] [Abstract][Full Text] [Related]
14. The Epstein-Barr Virus Enhancer Interaction Landscapes in Virus-Associated Cancer Cell Lines.
Ding W; Wang C; Narita Y; Wang H; Leong MML; Huang A; Liao Y; Liu X; Okuno Y; Kimura H; Gewurz B; Teng M; Jin S; Sato Y; Zhao B
J Virol; 2022 Sep; 96(18):e0073922. PubMed ID: 36094314
[TBL] [Abstract][Full Text] [Related]
15. A nonclassic CCAAT enhancer element binding protein binding site contributes to alpha-methylacyl-CoA racemase expression in prostate cancer.
Zha S; Isaacs WB
Mol Cancer Res; 2005 Feb; 3(2):110-8. PubMed ID: 15755877
[TBL] [Abstract][Full Text] [Related]
16. Construction of prostate-specific expressed recombinant plasmids with high transcriptional activity of prostate-specific membrane antigen (PSMA) promoter/enhancer.
Zeng H; Wu Q; Li H; Wei Q; Lu Y; Li X; Wang F; Zhao F; Ding Z; Yang Y
J Androl; 2005; 26(2):215-21. PubMed ID: 15713827
[TBL] [Abstract][Full Text] [Related]
17. Disruption of a -35 kb Enhancer Impairs CTCF Binding and
Liu Q; Thoms JAI; Nunez AC; Huang Y; Knezevic K; Packham D; Poulos RC; Williams R; Beck D; Hawkins NJ; Ward RL; Wong JWH; Hesson LB; Sloane MA; Pimanda JE
Clin Cancer Res; 2018 Sep; 24(18):4602-4611. PubMed ID: 29898989
[No Abstract] [Full Text] [Related]
18. Penguin: A tool for predicting pseudouridine sites in direct RNA nanopore sequencing data.
Hassan D; Acevedo D; Daulatabad SV; Mir Q; Janga SC
Methods; 2022 Jul; 203():478-487. PubMed ID: 35182749
[TBL] [Abstract][Full Text] [Related]
19. The leukemic oncogene EVI1 hijacks a MYC super-enhancer by CTCF-facilitated loops.
Ottema S; Mulet-Lazaro R; Erpelinck-Verschueren C; van Herk S; Havermans M; Arricibita Varea A; Vermeulen M; Beverloo HB; Gröschel S; Haferlach T; Haferlach C; J Wouters B; Bindels E; Smeenk L; Delwel R
Nat Commun; 2021 Sep; 12(1):5679. PubMed ID: 34584081
[TBL] [Abstract][Full Text] [Related]
20. Predict long-range enhancer regulation based on protein-protein interactions between transcription factors.
Wang H; Huang B; Wang J
Nucleic Acids Res; 2021 Oct; 49(18):10347-10368. PubMed ID: 34570239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
